This interview discusses anticoagulant reversal strategies in ICH and the current challenges and latest insights. The interview was conducted during ESOC 2024 at the ESOC studios, featuring Professor Thorsten Steiner & Dr David Seiffge
This discussion is supported by an unrestricted medical education grant from AstraZeneca and was conducted during ESOC 2024 Congress at the ESOC studios
Learning objectives from this video:
- Recognise the risk factors for intracerebral haemorrhage (ICH), particularly in patients prescribed oral anticoagulation, including the importance of timely diagnosis for effective haemostasis.
- State the challenges from the 2019 guidelines and discuss the remaining clinical unmet needs.
- Recall the guidelines on managing ICH in patients with prescribed oral anticoagulants.
- Discuss recent trials exploring reversal of FXa-inhibitors for efficacy and safety.